David is a partner and focuses on investments in novel therapeutics, often those that are near to first in human clinical testing.

Since joining Atlas in 2010, David has co-founded and served as chief executive officer of numerous companies including Arteaus Therapeutics acquired by Eli Lilly in 2014, Annovation Biopharma acquired by The Medicines Company in 2015, and was a founding board member of both Delinia acquired by Celgene in 2017, and Cadent Therapeutics acquired by Novartis in 2021. David is a co-founder and board member of Q32 Bio (NASDAQ: QTTB) and Vima Therapeutics, and also sits on the boards of Affinia Therapeutics, Aerovate (NASDAQ: AVTE), Comanche Biopharma, Trace Neuroscience, and TRIANA Biomedicines. He was previously a board director of Surface Oncology acquired by Coherus (NASDAQ: CHRS), Xilio Therapeutics (NASDAQ: XLO), and a board observer at Day One Biopharmaceuticals (NASDAQ: DAWN).

In addition, David serves or has served as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the Tri-Institutional Therapeutics Discovery Institute (comprised of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Cornell Medical Center), and the American Heart Association’s One Brave Idea. He is also a founding board member of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which his wife Courtney founded in 2009.

He earned his B.A. with honors from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in internal medicine at Massachusetts General Hospital.